Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913724 | 0.91 | MAPT (0.56) | ABCG2MAPTTP53TDP1POLB | |
| SCHEMBL4914836 | 0.89 | TP53 (0.69) | ABCG2MAPTTP53TDP1POLB | |
| SCHEMBL4908142 | 0.88 | TDP1 (0.64) | MAPTTP53TDP1POLBUSP2 | |
| SCHEMBL4907560 | 0.87 | KDM4E (0.64) | ABCG2MAPTTP53TDP1POLB | |
| SCHEMBL4914786 | 0.86 | TDP1 (0.55) | ABCG2MAPTTP53TDP1POLB | |
| SCHEMBL4913824 | 0.85 | BCL6 (0.62) | ABCG2MAPTTP53TDP1POLB | |
| SCHEMBL4908834 | 0.85 | TDP1 (0.54) | ABCG2MAPTTP53TDP1POLB | |
| SCHEMBL4908031 | 0.85 | HTR2A (0.57) | ABCG2MAPTTP53TDP1POLB | |
| SCHEMBL4910531 | 0.83 | TDP1 (0.51) | MAPTTDP1POLBUSP2ALOX15 | |
| SCHEMBL4904189 | 0.81 | NPY5R (0.57) | ABCG2MAPTTP53TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861388-B1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | SANIONA AS (DK) | 2017-07-05 | — | — | EP | claimed |
| US-8252806-B2 | 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease | NEUROSEARCH A/S (DK) | 2012-08-28 | — | — | US | claimed |
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | NEUROSEARCH A/S (DK) | 2008-11-06 | — | — | US | claimed |
| CN-101115736-A | Potassium channel modulating agents and their medical use | NEUROSEARCH AS (DK) | 2008-01-30 | — | — | CN | claimed |
| EP-1861388-B1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | SANIONA AS (DK) | 2017-07-05 | — | — | EP | disclosed |
| US-8252806-B2 | 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-propylamine; 2-(3,5-Dimethyl-pyrazol-1-yl)-quinazolin-4-yl]-(4-morpholin-4-yl-phenyl)-amine; respiratory diseases, epilepsy, convulsions, seizures, gastrointestinal dysfunction, ischaemia, psychosis, schizophrenia, anxiety, depression, Alzheimer's disease | NEUROSEARCH A/S (DK) | 2012-08-28 | — | — | US | disclosed |
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | NEUROSEARCH A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| CN-101115736-A | Potassium channel modulating agents and their medical use | NEUROSEARCH AS (DK) | 2008-01-30 | — | — | CN | disclosed |
| EP-1861388-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097441-A1 | POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275045-A1 | Potassium Channel Modulating Agents and Their Medical Use | KCND2, KCNN3, KCNJ2 | ABCG2 3090/4885MAPT 981/4885TP53 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.